MELBOURNE, Australia, May 27, 2014 /PRNewswire via COMTEX/ -- MELBOURNE, Australia, May 27, 2014 /PRNewswire/ --
Expanded SAB will oversee development of EMA401, Company’s lead program for treating chronic pain
Spinifex Pharmaceuticals, a pain drug development company, today announces that three internationally acclaimed scientists in chronic pain research have joined the Company’s Scientific Advisory Board (SAB).
Help employers find you! Check out all the jobs and post your resume.
